Cargando…

The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data

Literature regarding the effect of biologics on the course of mycosis fungoides (MF) is scarce. This multicentre study analysed retrospective data on 19 patients with MF, who were treated with biologics; 12 for inflammatory conditions coexisting with MF, and 7 for MF misdiagnosed as an inflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales: AMITAY-LAISH, Iris, GUENOVA, Emmanuella, ORTIZ-ROMERO, Pablo L., VICO-ALONSO, Cristina, ROZATI, Sima, GESKIN, Larisa J., NIKOLAOU, Vasiliki, PAPADAVID, Evangelia, BARZILAI, Aviv, PAVLOVSKY, Lev, DIDKOVSKY, Elena, NAVEH, Hadas PRAG, AKILOV, Oleg E., HODAK, Emmilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234989/
https://www.ncbi.nlm.nih.gov/pubmed/32965506
http://dx.doi.org/10.2340/00015555-3642
_version_ 1784736208164749312
author AMITAY-LAISH, Iris
GUENOVA, Emmanuella
ORTIZ-ROMERO, Pablo L.
VICO-ALONSO, Cristina
ROZATI, Sima
GESKIN, Larisa J.
NIKOLAOU, Vasiliki
PAPADAVID, Evangelia
BARZILAI, Aviv
PAVLOVSKY, Lev
DIDKOVSKY, Elena
NAVEH, Hadas PRAG
AKILOV, Oleg E.
HODAK, Emmilia
author_facet AMITAY-LAISH, Iris
GUENOVA, Emmanuella
ORTIZ-ROMERO, Pablo L.
VICO-ALONSO, Cristina
ROZATI, Sima
GESKIN, Larisa J.
NIKOLAOU, Vasiliki
PAPADAVID, Evangelia
BARZILAI, Aviv
PAVLOVSKY, Lev
DIDKOVSKY, Elena
NAVEH, Hadas PRAG
AKILOV, Oleg E.
HODAK, Emmilia
author_sort AMITAY-LAISH, Iris
collection PubMed
description Literature regarding the effect of biologics on the course of mycosis fungoides (MF) is scarce. This multicentre study analysed retrospective data on 19 patients with MF, who were treated with biologics; 12 for inflammatory conditions coexisting with MF, and 7 for MF misdiagnosed as an inflammatory skin disease. Eight patients were treated with anti-tumour necrosis factor-α-monotherapy; 6 had early-stage MF, in 3 patients MF preceded and in 3 MF was diagnosed after initiation of biologics, with no stage-progression or with stable disease, respectively (median treatment time concurrent with MF 57 months). Two patients had advanced stage MF: IIB, treated for 15 months with no stage-progression, and IVA1, treated for 8 months, died of disease 10 months later. The other 11/19 patients received anti-interleukin-17A and/or antiinterleukin-12/23 or anti-interleukin-23 (with/without anti-tumour necrosis factor-α/anti-interleukin-4/13), with stageprogression in 8 patients after a median of 8 months’ treatment. Although, in general, biologics should be avoided in patients with MF, these results indicate that anti-tumour necrosis factor-α-monotherapy might not aggravate the disease course in early-stage patients. Interleukin-17A, interleukin-12/23 and interleukin-23 pathway-blockers may prompt progression of MF.
format Online
Article
Text
id pubmed-9234989
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Society for Publication of Acta Dermato-Venereologica
record_format MEDLINE/PubMed
spelling pubmed-92349892022-10-20 The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data AMITAY-LAISH, Iris GUENOVA, Emmanuella ORTIZ-ROMERO, Pablo L. VICO-ALONSO, Cristina ROZATI, Sima GESKIN, Larisa J. NIKOLAOU, Vasiliki PAPADAVID, Evangelia BARZILAI, Aviv PAVLOVSKY, Lev DIDKOVSKY, Elena NAVEH, Hadas PRAG AKILOV, Oleg E. HODAK, Emmilia Acta Derm Venereol Clinical Report Literature regarding the effect of biologics on the course of mycosis fungoides (MF) is scarce. This multicentre study analysed retrospective data on 19 patients with MF, who were treated with biologics; 12 for inflammatory conditions coexisting with MF, and 7 for MF misdiagnosed as an inflammatory skin disease. Eight patients were treated with anti-tumour necrosis factor-α-monotherapy; 6 had early-stage MF, in 3 patients MF preceded and in 3 MF was diagnosed after initiation of biologics, with no stage-progression or with stable disease, respectively (median treatment time concurrent with MF 57 months). Two patients had advanced stage MF: IIB, treated for 15 months with no stage-progression, and IVA1, treated for 8 months, died of disease 10 months later. The other 11/19 patients received anti-interleukin-17A and/or antiinterleukin-12/23 or anti-interleukin-23 (with/without anti-tumour necrosis factor-α/anti-interleukin-4/13), with stageprogression in 8 patients after a median of 8 months’ treatment. Although, in general, biologics should be avoided in patients with MF, these results indicate that anti-tumour necrosis factor-α-monotherapy might not aggravate the disease course in early-stage patients. Interleukin-17A, interleukin-12/23 and interleukin-23 pathway-blockers may prompt progression of MF. Society for Publication of Acta Dermato-Venereologica 2020-09-30 /pmc/articles/PMC9234989/ /pubmed/32965506 http://dx.doi.org/10.2340/00015555-3642 Text en © 2020 Acta Dermato-Venereologica https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the CC BY-NC license
spellingShingle Clinical Report
AMITAY-LAISH, Iris
GUENOVA, Emmanuella
ORTIZ-ROMERO, Pablo L.
VICO-ALONSO, Cristina
ROZATI, Sima
GESKIN, Larisa J.
NIKOLAOU, Vasiliki
PAPADAVID, Evangelia
BARZILAI, Aviv
PAVLOVSKY, Lev
DIDKOVSKY, Elena
NAVEH, Hadas PRAG
AKILOV, Oleg E.
HODAK, Emmilia
The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data
title The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data
title_full The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data
title_fullStr The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data
title_full_unstemmed The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data
title_short The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data
title_sort course of mycosis fungoides under cytokine pathway blockers: a multicentre analysis of real-life clinical data
topic Clinical Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234989/
https://www.ncbi.nlm.nih.gov/pubmed/32965506
http://dx.doi.org/10.2340/00015555-3642
work_keys_str_mv AT amitaylaishiris thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT guenovaemmanuella thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT ortizromeropablol thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT vicoalonsocristina thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT rozatisima thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT geskinlarisaj thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT nikolaouvasiliki thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT papadavidevangelia thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT barzilaiaviv thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT pavlovskylev thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT didkovskyelena thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT navehhadasprag thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT akilovolege thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT hodakemmilia thecourseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT amitaylaishiris courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT guenovaemmanuella courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT ortizromeropablol courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT vicoalonsocristina courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT rozatisima courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT geskinlarisaj courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT nikolaouvasiliki courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT papadavidevangelia courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT barzilaiaviv courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT pavlovskylev courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT didkovskyelena courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT navehhadasprag courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT akilovolege courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata
AT hodakemmilia courseofmycosisfungoidesundercytokinepathwayblockersamulticentreanalysisofreallifeclinicaldata